Mechanisms that contribute to drug resistance in TNBC, including primary and adaptive drug resistance, can be summed up in the following three points: (i) weaken immunogenicity of the tumor; (ii) diminished antigen presentation by MHC; (iii) reduced recruitment and infiltration of immune cells. Here, HLA-C is linked to neoplasm.